The Manila Times1h
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in ...
The American Journal of Managed Care4d
Second CRL for Rivoceranib/Camrelizumab for Unresectable HCC
Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...
Precision Medicine Online1d
Elevation Oncology Terminates CLDN18.2-Targeted ADC, Reduces Workforce
The company said initial efficacy results from a Phase I trial did not provide a competitive benefit-risk profile in CLDN18.2-positive gastric and gastroesophageal cancer.
gut.bmj21d
IDDF2023-ABS-0169 Multi-omics profiling of human liver donors identifies the risks towards post-transplant diabetes mellitus
Results PTDM is characterized by a change of the VEGFA-VEGFR2 pathway, which is regulated by both miRNA and methylation in the donor’s liver. Recipients in the highest tertiles of donor T2D ...
Biotechs emerging from stealth take aim at pharma’s prime targets
The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.
Yahoo Finance1d
Elevation Oncology, Inc. (ELEV)
After hours: March 25 at 7:59:47 PM EDT Loading Chart for ELEV ...
Frontiers19d
Pharmacophore screening, molecular docking, and MD simulations for identification of VEGFR-2 and c-Met potential dual inhibitors
Introduction: The vascular endothelial growth factor receptor 2 (VEGFR-2) and the mesenchymal-epithelial transition factor (c-Met) are critical in the pathogenesis and progression of various cancers ...